Showing results 1 - 9 of 9
At GJE our specialist and highly experienced biotech patent attorneys have a deep understanding of the commercial realities of the sector. We appreciate the strategic value of IP to a biotech company...
GJE is pleased to announce that the firm has formed an alliance with the German patent and trade mark firm Wächtershäuser & Hartz (W&H)...
Thursday 14 March 2024 I 6:00 pm (London UK – GMT) GJE look forward to hosting the next Biotech Buddies networking event at our office in Broadgate Tower. Several members of our chemistry and life s...
On 21 March, Imago BioSciences, Inc., a clinical-stage biotechnology company developing innovative treatments for myeloid diseases, announced a $40 million Series B financing led by Omega Funds, a GJE...
We set out the key things for innovators and applicants to consider when patenting gene editors in Europe....
We explore the therapeutic indications addressed by Chimeric Antigen Receptors (CARs) and CAR T-cell therapy and consider patent protection at the EPO...
The UK’s venture capital (VC) landscape is undergoing a transformative shift, as recent trends and investment strategies highlight the critical role of intellectual property (IP) in securing funding...
This year, National DNA Day will be celebrated on 25 April 2024, commemorating Watson and Crick’s publication of the double helix structure of DNA on the same day in 1953 [1] and the imminent comple...
We are delighted to announce that Ross Cummings and Ian Jones have joined the Partnership. Ross Cummings joined GJE in 2017, having previously worked at another top tier firm of patent and trade mark ...